Lonzo Suhr

  • Lonzo Suhr posted an update 3 days, 1 hour ago

    Moreover, the new definition of drug resistant epilepsy was failure of adequate trials of two tolerated and appropriately chosen and used AED schedules to achieve sustained seizure freedom. In all eligible studies, types of AEDs were also variable. Moreover, drug-response was defined as patients with no seizure for more than three times the…[Read more]

  • Lonzo Suhr posted an update 3 days, 1 hour ago

    Meanwhile, the potent anti-platelet activity of K-134 also make it a potential alternative agent for preventing secondary cerebral infarction because antiplatelet therapy for secondary stroke prevention has been proved to be beneficial in clinical trials. Moreover, a double-blind, randomized trial of 4-MDM cilostazol and aspirin demonstrated that…[Read more]

  • Lonzo Suhr posted an update 4 days ago

    Meanwhile, the potent anti-platelet activity of K-134 also make it a potential alternative agent for preventing secondary cerebral infarction because antiplatelet therapy for secondary stroke prevention has been proved to be beneficial in clinical trials. Moreover, a double-blind, randomized trial of cilostazol and aspirin demonstrated that…[Read more]

  • Lonzo Suhr posted an update 4 days, 19 hours ago

    Moreover, the new definition of drug resistant epilepsy was failure of adequate trials of two tolerated and appropriately chosen and used AED schedules to achieve sustained seizure freedom. In all eligible studies, types of AEDs were also variable. Moreover, drug-response was defined as patients with no seizure for more than three times the…[Read more]

  • Lonzo Suhr posted an update 4 days, 19 hours ago

    Additionally, our study includes a mixed population of patients treated mTOR inhibitors-based combination therapy or mTOR inhibitors alone, and patients received placebo or non-placebo therapy were also included in our study. Therefore, the treatment design is not the same in all arms, and it might be another source of heterogeneity. Finally, it…[Read more]

  • Lonzo Suhr posted an update 4 days, 19 hours ago

    The meta-analysis is a powerful statistical tool to estimate the incidence and risk of those uncommon serious drug-related toxicities and this approach has been utilized to demonstrate an increased risk in treatment related mortality with bevacizumab and VEGFR-TKIs in previous researches. To the best of our knowledge, this is the first…[Read more]

  • Lonzo Suhr posted an update 5 days, 18 hours ago

    Additionally, our study includes a mixed population of patients treated mTOR inhibitors-based combination therapy or mTOR inhibitors alone, and patients received placebo or non-placebo therapy were also included in our study. Therefore, the treatment design is not the same in all arms, and it might be another source of heterogeneity. Finally, it…[Read more]

  • Lonzo Suhr posted an update 5 days, 18 hours ago

    Additionally, our study includes a mixed population of patients treated mTOR inhibitors-based combination therapy or mTOR inhibitors alone, and patients received placebo or non-placebo therapy were also included in our study. Therefore, the treatment design is not the same in all arms, and it might be another source of heterogeneity. Finally, it…[Read more]

  • Lonzo Suhr posted an update 5 days, 18 hours ago

    Meanwhile, the potent anti-platelet activity of K-134 also make it a potential alternative agent for preventing secondary cerebral infarction because antiplatelet therapy for secondary stroke prevention has been proved to be beneficial in clinical trials. Moreover, a double-blind, randomized trial of cilostazol and aspirin demonstrated that…[Read more]

  • Lonzo Suhr posted an update 6 days, 20 hours ago

    Additionally, our study includes a mixed population of patients treated mTOR inhibitors-based combination therapy or mTOR inhibitors alone, and patients received placebo or non-placebo therapy were also included in our study. Therefore, the treatment design is not the same in all arms, and it might be another source of heterogeneity. Finally, it…[Read more]

  • Lonzo Suhr posted an update 6 days, 21 hours ago

    The meta-analysis is a powerful statistical tool to estimate the incidence and risk of those uncommon serious drug-related toxicities and this approach has been utilized to demonstrate an increased risk in treatment related mortality with bevacizumab and VEGFR-TKIs in previous researches. To the best of our knowledge, this is the first…[Read more]

  • Lonzo Suhr posted an update 1 week, 2 days ago

    Additionally, our study includes a mixed population of patients treated mTOR inhibitors-based combination therapy or mTOR inhibitors alone, and patients received placebo or non-placebo therapy were also included in our study. Therefore, the treatment design is not the same in all arms, and it might be another source of heterogeneity. Finally, it…[Read more]

  • Lonzo Suhr posted an update 1 week, 2 days ago

    Moreover, the new definition of drug resistant epilepsy was failure of adequate trials of two tolerated and appropriately chosen and used AED schedules to achieve sustained seizure freedom. In all eligible studies, types of AEDs were also variable. Moreover, drug-response was defined as patients with no seizure for more than three times the…[Read more]

  • Lonzo Suhr posted an update 1 week, 2 days ago

    Meanwhile, the potent anti-platelet activity of K-134 also make it a potential alternative agent for preventing secondary cerebral infarction because antiplatelet therapy for secondary stroke prevention has been proved to be beneficial in clinical trials. Moreover, a double-blind, randomized trial of cilostazol and aspirin demonstrated that…[Read more]

  • Lonzo Suhr posted an update 1 week, 4 days ago

    Additionally, our study includes a mixed population of patients treated mTOR inhibitors-based combination therapy or mTOR inhibitors alone, and patients received placebo or non-placebo therapy were also included in our study. Therefore, the treatment design is not the same in all arms, and it might be another source of heterogeneity. Finally, it…[Read more]

  • Lonzo Suhr posted an update 1 week, 4 days ago

    Moreover, the new definition of drug resistant epilepsy was failure of adequate trials of two tolerated and appropriately chosen and used AED schedules to achieve sustained seizure freedom. In all eligible studies, types of AEDs were also variable. Moreover, drug-response was ABT-751 hydrochloride defined as patients with no seizure for more than…[Read more]

  • Lonzo Suhr posted an update 1 week, 4 days ago

    Meanwhile, the potent anti-platelet activity of K-134 also make it a potential alternative agent for preventing secondary cerebral infarction because antiplatelet therapy for secondary stroke prevention has been proved to be beneficial in clinical trials. Moreover, a double-blind, randomized trial of cilostazol and aspirin demonstrated that…[Read more]

  • Lonzo Suhr posted an update 1 week, 5 days ago

    Additionally, our study includes a mixed population of patients treated mTOR inhibitors-based combination therapy or mTOR inhibitors alone, and patients received placebo or non-placebo therapy were also included in our study. Therefore, the treatment design is not the same in all arms, and it might be another source of heterogeneity. Finally, it…[Read more]

  • Lonzo Suhr posted an update 1 week, 5 days ago

    The meta-analysis is a powerful statistical tool to estimate the incidence and risk of those uncommon serious drug-related toxicities and this approach has been utilized to demonstrate an increased risk in treatment related mortality with bevacizumab and VEGFR-TKIs in previous researches. To the best of our knowledge, this is the first…[Read more]

  • Lonzo Suhr posted an update 1 week, 5 days ago

    Moreover, the new definition of drug resistant epilepsy was failure of adequate trials of two tolerated and appropriately chosen and used AED schedules to achieve sustained seizure freedom. In all eligible studies, types of AEDs were also variable. Moreover, drug-response was defined as patients with no seizure for more than three times the…[Read more]

  • Load More
Skip to toolbar